揭牌仪式结束后，与会领导、嘉宾实地参观了口腔医院，详细了解医院的整体布局、科室设置等情况。 沈阳医学院党委副书记、校长吴玉东表示："未来，学校将充分发挥高校科技创新和医院临床资源优 势，推进口腔医学教育和临床实践深度交叉融合，建设特色专科集群，推动学科建设和人才培养再上新 台阶。" （来源：沈阳日报） 近年来，市委、市政府始终高度重视卫生健康事业的发展，积极推进大学附属医院高质量发展。2024年 3月，沈阳市口腔医院被划归为沈阳医学院直属附属口腔医院。依托这一重要平台，沈阳医学院成功获 批口腔医学专业硕士点，顺利通过教育部本科教育教学审核评估，为学校冲刺更名医科大学、备战2026 年口腔医学专业认证工作奠定了坚实基础。此次揭牌仪式的举办，不仅是沈阳医学院在完善学科布局、 深化临床教学改革、服务社会健康需求方面迈出新的坚实步伐的标志，也是沈阳整合优质资源、打造高 水平专科医疗服务新高地，推动医疗卫生服务体系优化升级的重要表现。 转自：沈阳日报 本报讯（沈阳日报、沈报全媒体记者杨洋）1月8日，沈阳医学院附属口腔医院揭牌仪式在该院浑南院区 举办。 ...

证券之星消息，截至2026年1月7日收盘，皓宸医疗(002622)报收于3.04元，下跌2.88%，换手率4.11%， 成交量34.49万手，成交额1.06亿元。 1月7日的资金流向数据方面，主力资金净流入106.35万元，占总成交额1.01%，游资资金净流入180.18 万元，占总成交额1.71%，散户资金净流出286.52万元，占总成交额2.71%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-07 | 3.04 | -2.88% | 106.35万 | 1.01% | 180.18万 | 1.71% | -286.52万 | -2.71% | | 2026-01-06 | 3.13 | 2.62% | 358.69万 | 2.63% | 845.97万 | 6.20% | -1204.66万 | -8.83% | | 2026-01-05 | 3.05 | 2.69% ...

证券日报网讯12月17日，通策医疗（600763）在互动平台回答投资者提问时表示，公司是一家以提供医 疗服务为主营业务的口腔医疗集团，中国本土市场潜力大，根据公司的业务模式与发展战略，当前的发 展重心是深耕国内口腔医疗服务市场，持续强化在浙江省内的领先地位，并稳步推进在全国重点区域的 布局。 ...

Core Viewpoint - 瑞尔集团's stock rose over 7% in early trading, reflecting positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Financial Performance - The company anticipates a pre-tax profit of no less than 20 million HKD for the reporting period, a significant increase from 7.4 million HKD in the same period last year [1] - The profit increase is attributed to operational improvements driven by AI-enabled clinical and business management systems, a rebound in patient demand and service volume, and strict cost reduction and efficiency enhancement measures [1]

Core Viewpoint - 瑞尔集团预计在2026财年半年报中实现除所得税前利润不少于2000万元，较上年同期的740万元显著提升，主要得益于AI赋能的运营提升、患者需求回升及严格的降本增效计划 [1] Financial Performance - 瑞尔集团在2025财年半年报中实现收入约16.88亿元，同比仅减少3.3%，净利润增至1620万元，同比增长20.5% [11] - 公司在2024财年中，累计回购1736.35万股，占总股本比例达到3.08% [5] - 2024年，瑞尔集团的股价经历波动，尽管回购未能有效支撑股价，但在回购策略调整后，股价有所回升 [7][10] Market Conditions - 2024年国内医疗健康产业融资交易数量下降37.6%，融资总额减少33%，显示出行业整体遇冷 [9] - 口腔行业在2024年仅发生13起融资，占总融资交易数的1.6%，融资总额约9亿元，占总融资额的12.32% [9] - 行业内中小口腔诊所面临批量倒闭，2024年注销量同比增长约45% [9] Strategic Shift - 瑞尔集团的发展策略从扩张转向稳健，专注于现有诊所的精细化管理，取得一定成效 [10] - 公司在2025财年半年报中显示，扩店放缓在一定程度上缓解了对盈利的负面影响，表现在实现正增长 [10][11] Stock Performance - 瑞尔集团股价在2023年7月达到阶段性高点2.90港元后，经历了近4个月的下行周期，最低跌至1.59港元，跌幅达45.17% [1] - 随着港股通资金抛压影响减弱，瑞尔集团的持股比例在9月后几乎未再减少，显示出市场信心的恢复 [2][4]

Core Viewpoint - 瑞尔集团 expects to achieve a pre-tax profit of no less than 20 million yuan for the first half of the 2026 fiscal year, a significant increase from 7.4 million yuan in the same period last year, primarily due to AI-enabled operational improvements, rising patient demand, and strict cost control measures [1] Financial Performance - The company reported a pre-tax profit expectation of at least 20 million yuan for the first half of the 2026 fiscal year, compared to 7.4 million yuan in the previous year [1] - Revenue for the first half of the 2025 fiscal year was approximately 1.688 billion yuan, a year-on-year decrease of 3.3%, while net profit increased to 16.2 million yuan, a year-on-year growth of 20.5% [14] Stock Performance - Following the earnings announcement, the stock price rose by 9.43%, ending a six-day decline, after reaching a low of 1.59 HKD, down 45.17% from a peak of 2.90 HKD [1] - The company has been in a downtrend for nearly four months, with a significant drop in stock price despite previous recovery efforts [1][8] Market Dynamics - The domestic healthcare investment market saw a 37.6% decrease in financing transactions in 2024, with the oral healthcare sector facing challenges, including a 45% increase in the number of clinic closures [10][11] - The average profit margin in the oral healthcare industry has plummeted from 28% in 2019 to 9% [10] Strategic Shift - The company has shifted its strategy from aggressive expansion to a focus on optimizing existing clinics, which has led to improved management and operational efficiency [12][14] - The number of clinics remained stable, with 123 locations across 15 cities, indicating a pause in expansion to mitigate negative impacts on profitability [13][14] Share Buyback Strategy - The company engaged in share buybacks to stabilize market confidence, repurchasing 17.36 million shares in 2024, representing 3.08% of total shares [5] - A "small step fast run" strategy was adopted for buybacks in 2024, with 21 transactions totaling approximately 1.543 million shares, or 0.27% of total shares [6][8] Valuation Metrics - The company's price-to-book (PB) ratio is currently at 0.51, significantly lower than the industry average of 1.63, indicating potential for stock price recovery [14]

Core Viewpoint - The recent announcement by Haocen Medical indicates a change in control, leading to a state of no actual controller, amidst ongoing financial struggles and legal disputes. Group 1: Control Change - Haocen Medical's largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, has undergone a control change, resulting in the company having no actual controller [1][3] - The control change stems from a long-standing cooperation dispute between Huiyin Aofeng and Beijing Shoutuo Ronghui, which was confirmed by a court ruling [2][3] Group 2: Financial Performance - Haocen Medical has reported continuous losses for five consecutive years, with cumulative losses exceeding 700 million yuan from 2020 to 2024 [6] - In the first three quarters of 2025, the company achieved a revenue of 527 million yuan, a year-on-year decrease of 17.0%, with a net profit loss of 26.41 million yuan, a decline of 295.7% [7] Group 3: Business Challenges - The decline in the core dental medical service business is a significant factor in the company's revenue drop, with this segment accounting for 91.98% of total revenue and experiencing a 17.39% year-on-year decrease in the first half of 2025 [8] - Haocen Medical's subsidiary, Delun Medical, has faced a court-ordered freeze on 51% of its shares due to a creditor dispute, which poses risks to the company's operations [9] Group 4: Attempts at Recovery - The company has made unsuccessful attempts to recover financially, including failed auctions of bank shares and attempts to secure loans, which have not alleviated its financial strain [10]

Core Viewpoint - Haocen Medical Technology Co., Ltd. has reported a significant decline in revenue and a drastic drop in net profit, alongside a court-ordered freeze on the equity of its key subsidiary, Delun Medical [1][2][6]. Financial Performance - For the first three quarters of 2025, Haocen Medical achieved a revenue of 527 million yuan, a year-on-year decrease of 17.0%, and a net loss attributable to shareholders of 26.41 million yuan, a decline of 295.7% [2][5]. - In Q3 2025, the company reported a revenue of 213 million yuan, down 15.7% year-on-year, and a net loss of 2.66 million yuan, a decrease of 120.5% [2]. Revenue Breakdown - The core issue behind the performance decline is attributed to the drop in the oral medical service segment, which constitutes 91.98% of total revenue. This segment saw a revenue decline of 17.39% in the first half of 2025 [3]. Legal and Asset Issues - The 51% equity stake in Delun Medical, a key subsidiary, has been frozen by the court due to a creditor's revocation dispute, with the freeze lasting for two years [6][8]. - The legal dispute stems from a loan agreement with Wenzhou Bank, where the creditor claims that the transfer of equity to another subsidiary adversely affected their ability to recover the debt [7][8]. Attempts at Financial Recovery - Haocen Medical has attempted various self-rescue measures, including asset auctions and loan applications, but these efforts have not yielded positive results [9]. - The company is currently seeking to negotiate debt resolution strategies with creditors, including debt reduction and restructuring, but has not made substantial progress [9].

Core Viewpoint - Haocen Medical, established in 1998 and listed in 2011, operates in the medical services sector with a focus on oral healthcare, but its financial performance lags behind industry leaders [1][2]. Financial Performance - For Q3 2025, Haocen Medical reported revenue of 527 million yuan, ranking 14th in the industry, significantly lower than the top player Aier Eye Hospital's 17.48 billion yuan and second-place Meinian Health's 6.93 billion yuan [2]. - The company's main revenue source is oral medical services, generating 288 million yuan, accounting for 91.98% of total revenue, while industrial switch products contributed 24.11 million yuan (7.69%) and other income was 1.04 million yuan (0.33%) [2]. - The net profit for the same period was -31.03 million yuan, placing it 13th in the industry, far behind Aier Eye Hospital's 3.367 billion yuan and Tongce Medical's 616 million yuan [2]. Financial Ratios - As of Q3 2025, Haocen Medical's debt-to-asset ratio was 71.72%, up from 68.55% year-on-year and above the industry average of 46.74% [3]. - The gross profit margin stood at 47.72%, slightly down from 47.97% year-on-year but still above the industry average of 31.10% [3]. Management and Shareholder Information - The chairman, Lu Lu, has a salary of 1.2 million yuan for 2024, unchanged from 2023 [4]. - As of September 30, 2025, the number of A-share shareholders decreased by 4.97% to 46,200, while the average number of shares held per shareholder increased by 5.23% to 18,200 [5].

Core Viewpoint - The Shunyi District of Beijing is accelerating the construction of an international dental industry cluster, aiming to create a global hub for dental medical technology innovation and industry integration [1] Industry Development - Shunyi District is focusing on the pharmaceutical and health sectors as emerging industries, aligning with Beijing's strategy to build an international science and technology innovation center [1] - The district has gathered nearly 100 dental industry chain enterprises, covering the entire chain from research and development to production and services [1] Policy and Investment - The Shunyi District government has initiated the establishment of a dental industry fund in collaboration with enterprises, targeting areas such as dental medical devices, medical robots, core components, dental materials, artificial intelligence in dentistry, and dental medical services [1] - The district is leveraging policy advantages from the Beijing Tianzhu Comprehensive Bonded Zone to enhance institutional innovation and facilitate international procurement, testing, certification, and cross-border customs clearance [1] Future Plans - Shunyi District plans to further optimize the business environment and attract companies in dental materials, devices, and equipment to enhance the core competitiveness of the industry [1] - The goal is to build a dental industry cluster with global influence [1]